No abstract available.
Graft vs Host Disease*

No abstract available.
Graft vs Host Disease* ; Warts*

No abstract available.
Graft vs Host Disease* ; HLA-DR Antigens

No abstract available.
Graft vs Host Disease* ; Liver Transplantation*

Graft-versus-host disease occurs after the administration of foreign immunologically competent cells to an individual who is immunologically compromised. It is a clinical syndrome characterized by cutaneous changes, gastrointestinal dysfunction and liver dysfunction. Cutaneous graft-versus-host reaction is usually the earliest and certainly the most common form of the disease. The diagnosis of graft-versus-host disease is a complex clinicopathologic skill requiring considerable experience. There as yet appears to be no pathognomonic single clinical or histologic feature in the acute phase. In this review article, the definition, immunological aspects and. clinical features of graft-versus-host disease, diagnostic criteria of acute cutaneous graft-versus-host reaction and graft-versus-tumor effect are discussed.
Diagnosis ; Graft vs Host Disease ; Liver Diseases

Chimerism ; Graft vs Host Disease ; Liver Transplantation

No abstract available.
B-Lymphocytes ; Graft vs Host Disease

Subacute radiation dermatitis is a cutaneous disorder that occurs secondary to radiation exposure. It occurs after weeks to a few months from radiation exposure. Histologically, subacute radiation dermatitis presents with interface dermatitis that resembles graft-versus-host disease or a fixed drug eruption. The previous reports on this disease have usually been related to extensive or repeated coronary angiography. Herein, we report on a case of subacute radiation dermatitis that occurred 5 weeks after cardiac intervention therapy.
Coronary Angiography ; Dermatitis ; Drug Eruptions ; Fluoroscopy ; Graft vs Host Disease

PURPOSE: To evaluate the therapeutic effects of 0.03% tacrolimus eye drops on dry eye associated with chronic ocular graft-versus-host disease (GVHD). METHODS: This study included 24 eyes of 12 patients with refractory dry eye associated with chronic ocular GVHD who were unresponsive to topical steroid and 0.05% topical cyclosporine. The topical steroid and cyclosporine were discontinued for 2 weeks before treatment and 0.03% tacrolimus eye drops were applied twice a day for 1 month. Artificial tears, ointment, and lid cleanser were used in the same manner before initiating tacrolimus treatment. Ocular staining score, tear break-up time, ocular surface disease index (OSDI), and Schirmer I test score were evaluated. RESULTS: Ocular staining score, tear break-up time, and OSDI improved with statistical significance (p < 0.05) after 28 days of treatment. Schirmer I test did not show statistical improvement after treatment. CONCLUSIONS: The use of 0.03% tacrolimus eye drops were effective for refractory dry eye associated with chronic ocular GVHD.
Cyclosporine ; Graft vs Host Disease* ; Humans ; Ophthalmic Solutions* ; Tacrolimus* ; Tears

Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual efficacy of MSCs in various diseases has evoked a sense of discouragement. Therefore, we believe that MSC therapy may now be at a critical milestone for re-evaluation and re-consideration. In this review, we summarize the current status of MSC-based clinical trials and focus on the discrepancy between expected and actual outcome of MSC therapy from bench to bedside. Importantly, we discuss the underlying limitations of MSCs and suggest a new guideline for MSC therapy in hopes of improving their therapeutic efficacy.
Graft vs Host Disease ; Hope ; Mesenchymal Stromal Cells